학술논문
Subcutaneous Immunoglobulin 16.5% (Cutaquig) is Safe and Efficacious at Modified Dosing Regimens in Patients With Primary Immunodeficiency Disease
Document Type
Abstract
Author
Source
In The Journal of Allergy and Clinical Immunology February 2023 151(2) Supplement:AB326-AB326
Subject
Language
ISSN
0091-6749